SCHEMBL2363282

SCHEMBL2363282

Cc1ccnc(Nc2cccc(-c3cnc(NCc4ccccc4)o3)c2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.56
FLT1 P17948 5/20 0.56
FLT4 P35916 5/20 0.56
NOS2 P35228 1/20 0.53
SYK P43405 1/20 0.49
MAPT P10636 2/20 0.47
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47
RECQL P46063 1/20 0.47
AURKA O14965 1/20 0.42
RPS6KB1 P23443 1/20 0.42
AURKB Q96GD4 1/20 0.42
KARS1 Q15046 2/20 0.42
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
POLB P06746 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14673905 0.88 KDR (0.51) KDRFLT1FLT4NOS2SYK
SCHEMBL2227682 0.78 SYK (0.55) KDRFLT1FLT4SYKMAPT
SCHEMBL2228419 0.77 SYK (0.50) KDRFLT1FLT4SYKMAPT
SCHEMBL2363041 0.76 SYK (0.51) KDRFLT1FLT4SYKMAPT
SCHEMBL2363040 0.76 SYK (0.51) KDRFLT1FLT4SYKMAPT
SCHEMBL2279296 0.75 KARS1 (0.52) KDRFLT1NOS2SYKKARS1
SCHEMBL26307286 0.72 KDR (0.84) KDRFLT1FLT4
Gw632046X SCHEMBL5475472 0.72 KDR (1.00) KDRFLT1FLT4
SCHEMBL14673478 0.72 SYK (0.68) KDRFLT1FLT4SYKMAPT
SCHEMBL2227246 0.72 SYK (0.49) KDRFLT1FLT4SYKMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2523952-B1 OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2015-03-04 EP claimed
CN-102812022-A Thiazole and oxazole kinase inhibitors AB SCIENCE 2012-12-05 CN claimed
EP-2523952-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB Science (FR) 2012-11-21 EP claimed
WO-2011086085-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2011-07-21 WO claimed
EP-2523952-B1 OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2015-03-04 EP disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SYK, LTK, MERTK KDR 79/4885FLT1 9/4885FLT4 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.